Editas Medicine CFO resigns; Amy Parison appointed as CFO

Editas Medicine, Inc.

Erick Lucera resigns as EVP, CFO effective March 28, 2025.
Amy Parison, previously SVP Finance, appointed SVP, CFO and Treasurer effective March 28, 2025.
Parison receives $415k base salary, 40% target bonus, and option for 34,672 shares vesting monthly over 4 years.
Parison joined Editas in Aug 2022 as VP Finance, Corporate Controller, promoted to SVP Finance Jan 2025.
No arrangement or understanding behind Parison's selection; no reportable transactions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Erick Lucera

Executive Vice President, Chief Financial Officer

EDIT · Editas Medicine, Inc.

Effective: 2025-03-28
Successor: Amy Parison
Filed: March 20, 2025, 7:59 PM ET

On March 18, 2025, Erick Lucera, Executive Vice President, Chief Financial Officer of Editas Medicine, Inc. (the “Company”) informed the Company that he will be resigning from his position effective March 28, 2025.

Role change

Amy Parison

Senior Vice President, Chief Financial Officer and Treasurer

EDIT · Editas Medicine, Inc.

Effective: 2025-03-28
Filed: March 20, 2025, 7:59 PM ET

In connection with Mr. Lucera’s resignation, on March 19, 2025 the Company appointed Amy Parison, Senior Vice President, Finance as Senior Vice President, Chief Financial Officer and Treasurer of the Company, to be effective as of the close of business on March 28, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Erick Lucera departed as Executive Vice President, Chief Financial Officer at Editas Medicine, Inc..

Action: resigning
Role: Executive Vice President, Chief Financial Officer

Exact text from the filing

On March 18, 2025, Erick Lucera, Executive Vice President, Chief Financial Officer of Editas Medicine, Inc. (the “Company”) informed the Company that he will be resigning from his position effective March 28, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy Parison was appointed as Senior Vice President, Chief Financial Officer and Treasurer at Editas Medicine, Inc..

Action: appointed
Role: Senior Vice President, Chief Financial Officer and Treasurer

Exact text from the filing

In connection with Mr. Lucera’s resignation, on March 19, 2025 the Company appointed Amy Parison, Senior Vice President, Finance as Senior Vice President, Chief Financial Officer and Treasurer of the Company, to be effective as of the close of business on March 28, 2025.

View on SEC.gov

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001650664-25-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.